Finance

Lists
Outlook: 83.3% bullish·0.0% bearish
Go to analysis
ZYME:NASDAQ
Zymeworks Inc
$26.24
-0.87%
(-0.23) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZYME...
Open
$26.47
High
$26.75
Low
$25.82
Mkt. cap
1.81B
Avg. vol.
1.36M
Volume
774.98K
P/E ratio
50.20
52-wk high
$31.97
52-wk low
$18.20
EPS
$0.52
Beta
1.32
Shares outstanding
69.03M
No. of employees
279
Open
$26.47
High
$26.75
Low
$25.82
Mkt. cap
1.81B
Avg. vol.
1.36M
Volume
774.98K
P/E ratio
50.20
52-wk high
$31.97
52-wk low
$18.20
EPS
$0.52
Beta
1.32
Shares outstanding
69.03M
No. of employees
279
News stories
From web sources and news partners
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees279
Founded2003
HeadquartersMiddletown, Delaware, United States
SectorHealth Care
IndustryBiotechnology
Websitezymeworks.com
Analyst ratings
Based on 13 analysts giving stock ratings to ZYME in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ZYME in the last 3 months.
Highest
Current $26.24
$56.00 (+113.41%)
Average
$41.83 (+59.41%)
Lowest
$34.00 (+29.57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Cheng
J.P. Morgan
Buy
Maintained
$35.00
+33.4%
11/12/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$39.00
+48.6%
11/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$44.00
+67.7%
11/11/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$56.00
+113.4%
11/10/2026
Yaron Werber
TD Cowen
Buy
Maintained
$39.00
+48.6%
11/10/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$46.00
+75.3%
11/10/2026
Gregory Renza
Truist Financial
Buy
Maintained
$35.00
+33.4%
10/29/2026
David Martin PhD
Bloom Burton
Buy
Maintained
$38.00
+44.8%
10/28/2026
Akash Tewari
Jefferies
Buy
Maintained
$52.00
+98.2%
10/23/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$44.00
+67.7%
09/29/2026
Unknown Analyst
Jefferies
Buy
Maintained
$50.00
+90.5%
09/29/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$34.00
+29.6%
09/28/2026
Kalpit Patel
Wolfe Research
Buy
Initiated
-
-
09/17/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
$40.00
+52.4%
08/25/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$44.00
+67.7%
08/10/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$40.00
+52.4%
07/30/2026
Asthika Goonewardene
Truist Financial
Buy
Initiated
$28.00
+6.7%
06/09/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
$2.28 / $2.19
+4.33%beat
Revenue / Est. (USD)
256.46M / 221.01M
+16.04%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.52M
2.41M
4.59M
256.46M
Cost of goods sold
31.24M
34.46M
27.44M
35.38M
Cost of revenue
31.24M
34.46M
27.44M
35.38M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.43M
15.07M
19.34M
30.57M
Operating expense
15.43M
15.07M
19.34M
30.57M
Total operating expenses
46.67M
49.53M
46.77M
65.95M
Operating income
-44.15M
-47.12M
-42.18M
190.51M
Other non operating income
-18.00K
120.00K
196.00K
-138.00K
EBT including unusual items
-41.48M
-46.35M
-45.29M
173.25M
EBT excluding unusual items
-41.48M
-46.35M
-45.29M
186.16M
Income tax expense
-270.00K
-2.19M
-273.00K
-452.00K
Effective tax rate
0.65%
4.73%
0.60%
-0.26%
Other operating expenses
-
-
-
-
Net income
-41.21M
-44.16M
-45.02M
173.70M
Net profit margin
-1,638.53%
-1,833.97%
-980.81%
67.73%
Earnings per share
-0.55
-0.59
-0.62
2.28
Interest and investment income
2.98M
2.71M
3.29M
2.47M
Interest expense
-
-2.07M
-6.60M
-6.68M
Net interest expenses
2.98M
645.00K
-3.31M
-4.21M
Depreciation and amortization charges
-
-
-
-
EBITDA
-43.07M
-45.98M
-41.05M
192.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps